Abstracts tagged "cytokines"

Abstract Number: 2329 • 2017 ACR/ARHP Annual Meeting
Monocytes from Patients with Enthesitis Related Arthritis Produce High Levels of Pro-Inflammatory Cytokines: Role of Endogenous Ligands
Amita Aggarwal¹, Shruti Bhattacharya² and Ramnath Misra², ¹Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: HLA B27 and gut bacteria are postulated to play a role in pathogenesis of Enthesitis Related Arthritis. Gut microbes can activate monocytes/macrophages by TLR…
Abstract Number: 965 • 2017 ACR/ARHP Annual Meeting
Decoy Receptor 3 up-Regulates Cadherin 2 in Rheumatoid Synovial Fibroblasts
Koji Fukuda¹, Yasushi Miura^2,3, Shinya Hayashi², Toshihisa Maeda^1,4 and Ryosuke Kuroda¹, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Orthpaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ⁴Department of Immunology and Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand, LIGHT, and…
Abstract Number: 2332 • 2017 ACR/ARHP Annual Meeting
Biomarkers for the Diagnosis and the Identification of Risk of Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA)
Claudia Bracaglia¹, Denise Pires Marafon², Ivan Caiello³, Kathy de Graaf⁴, Maria Ballabio⁴, Walter Ferlin⁴, Sergio Davì⁵, Grant Schulert⁶, Angelo Ravelli⁷, Alexei A. Grom⁸, Robert Nelson⁴, Cristina de Min⁴ and Fabrizio De Benedetti², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁴NovImmune S.A., Geneva, Switzerland, ⁵University of Genova, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁶Pediatric Rheumatology, Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁷University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁸Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States Minor Outlying Islands
Background/Purpose: We have recently reported high levels of IFNγ and of the IFNγ-related chemokines, (CXCL9 and CXCL10) in patients with MAS (1). Methods: Circulating levels…
Abstract Number: 1027 • 2017 ACR/ARHP Annual Meeting
Quantification of Leukocytes’ Secretome to Guide Diagnosis and Treatment Options in Patients with Suspected Chronic Auto-Inflammatory Syndromes
Philippe A. Tessier¹, Marie-Pier Longchamps¹, Nathalie Amiable¹, Nathalie Pagé¹, Laetitia Michou², Louis Bessette², Paul R. Fortin¹, Alexandra Albert², Anne-Laure Chetaille² and Martin Pelletier¹, ¹Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ²Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada
Background/Purpose: Auto-inflammatory syndromes are inherited conditions characterized by recurrent inflammation (fever, abdominal pain, dermatitis, arthritis). Diagnosis and treatments are challenging as detection rate of mutations…
Abstract Number: 2339 • 2017 ACR/ARHP Annual Meeting
Expression of Type I and Type II Interferons Is Increased in Muscle Biopsies of Juvenile Dermatomyositis Patients and Related to Clinical and Histological Features
Rebecca Nicolai¹, Gian Marco Moneta², Silvia Rosina³, Chiara Fiorillo³, Denise Pires Marafon¹, Margherita Verardo⁴, Luisa Bracci Laudiero^5,6, Carlo Minetti^3,7, Angelo Ravelli^3,8 and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Roma, Italy, ³University of Genova, Genova, Italy, ⁴Unit of Neuromuscular and Neurodegenerative Disorders, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Roma, Italy, ⁵Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Roma, Italy, ⁶Institute of Translational Pharmacology, CNR, Rome, Italy, Rome, Italy, ⁷Pediatric Neurology and Muscular Disorders, Giannina Gaslini Institute, Genova, Italy, ⁸Rheumatology, Giannina Gaslini Institute, Genova, Italy
Background/Purpose: There is growing evidence for an involvement of interferons (IFNs) in the chronic inflammation that characterizes juvenile dermatomyositis (JDM). The aim of this study…
Abstract Number: 32 • 2017 ACR/ARHP Annual Meeting
Longitudinal Associations between Rheumatoid Factor and Ex Vivo Cytokine Production Reveal Novel Mechanistic Insights into Rheumatoid Arthritis
John M. Davis III¹, Cynthia S. Crowson², Keith L. Knutson³, Sara J. Achenbach⁴, Terry M. Therneau⁵, Eric L. Matteson⁶, Sherine E. Gabriel⁷ and Peter J. Wettstein⁸, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Immunology, Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic, Rochester, MN, ⁵Biostatistics, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁷Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁸Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Positive rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) identify a major rheumatoid arthritis (RA) subgroup, characterized by greater propensity to erosive joint damage…
Abstract Number: 1209 • 2017 ACR/ARHP Annual Meeting
Phospholipase A2 Group 5 Is a Potential Therapeutic Target for Osteoarthritis Treatment
Ming Liu¹, Andrew Furey², Weidong Zhang³, Sergei Likhodi², Edward Randell², Proton Rahman⁴ and Guangju Zhai², ¹Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³Jilin University, Changchun, China, ⁴Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada
Background/Purpose: We recently discovered that lysophosphotidylcholines (lysoPCs) to phosphotidylcholines (PCs) ratio was associated with knee osteoarthritis (OA), suggesting that the conversion of PCs to lysoPCs…
Abstract Number: 2346 • 2017 ACR/ARHP Annual Meeting
Chemokine Ligand 9 (CXCL9) [Monokine Induced By Gamma Interferon (MIG)] As a Predictor of Active Disease Status in Localized Scleroderma
Kathryn S. Torok¹, Qi Mi², Emily Mirizio³, Kaila Schollaert-Fitch¹, Mark Fritzler⁴ and Marvin J. Fritzler⁵, ¹Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, ³Pediatric Rhuematology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Eve Technologies, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Localized scleroderma (LS) is a fibrotic autoimmune disease of the skin and underlying tissues which can lead to disfiguring sequlea, especially in childhood-onset. Untreated…
Abstract Number: 9 • 2017 Pediatric Rheumatology Symposium
Biologically-Based Approach for Classifying Chronic Childhood Arthritis
Elham Rezaei¹, Daniel Hogan², Brett Trost², Anthony Kusalik², Susanne Benseler³, Gilles Boire⁴, David A. Cabral⁵, Bonnie Cameron⁶, Sarah Campillo⁷, Gaëlle Chédeville⁸, Paul Dancey⁹, Ciarán M. Duffy¹⁰, Karen N Watanabe Duffy¹¹, Janet Ellsworth¹², Simon Eng¹³, Brian M. Feldman¹⁴, John Gordon², Jaime Guzman¹⁵, Kristin Houghton¹⁶, Adam Huber¹⁷, Quaid Morris¹³, Bianca Lang¹⁸, Deborah M. Levy¹⁹, Loren Matheson²⁰, Kiem Oen²¹, Ross Petty²², Suzanne Ramsey²³, Johannes Roth²⁴, Dax Rumsey²⁵, Claire Saint-Cyr²⁶, Rayfel Schneider²⁷, Rosie Scuccimarri²⁸, Earl Silverman¹⁹, Lynn R. Spiegel²⁹, Elizabeth Stringer¹⁸, Shirley M.L. Tse³⁰, Lori Tucker³¹, Rae S.M. Yeung³² and Alan Rosenberg¹, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Pediatrics/Rm K4-121, BC Children's Hospital, Vancouver, BC, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Montreal Children's Hospital, Montreal, QC, Canada, ⁸Rheumatology, McGill University, Montreal, QC, Canada, ⁹Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹⁰Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹¹Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹²University of Alberta, Edmonton, AB, Canada, ¹³University of Toronto, Toronto, ON, Canada, ¹⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹⁶Rheumatology/Pediatrics, British Columbia Childrens Hos, Vancouver, BC, Canada, ¹⁷IWK Health Centre, Halifax, NS, Canada, ¹⁸Dalhousie University, Halifax, NS, Canada, ¹⁹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²⁰University of Saskatchewan, Ottawa, ON, Canada, ²¹University of Manitoba, Winnipeg, MB, Canada, ²²Pediatric Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²³Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ²⁴Pediatric Rheumatology, Children's Hospital Eastern On, Ottawa, ON, Canada, ²⁵Stollery Children's Hospital, Edmonton, AB, Canada, ²⁶Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada, ²⁷Division of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²⁸Division of Pediatric Rheumatology, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada, ²⁹Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ³⁰Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³¹Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, ³²Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of conditions that share chronic arthritis as a common characteristic. International uniformity in classifying JIA, based…
Abstract Number: 15L • 2016 ACR/ARHP Annual Meeting
Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis vulgaris and Normalizes Skin Pathology Via Concurrent Regulation of IL-17 and IL-10 Levels
Alexandra Zanin-Zhorov¹, Jonathan Weiss¹, Alissa Trzeciak¹, Carmen Arencibia¹, Seetharam Polimera¹, Wei Chen¹, Jingya Zhang¹, Melanie Nyuydzefe¹, Judilyn Fuentes-Duculan², Kathleen Bonifacio², Norma Kunjravia², Inna Cueto², Mark Berger¹, James Krueger², Samuel Waksal¹ and John Ryan¹, ¹Kadmon, New York, NY, ²Rockefeller University, New York, NY

Background/Purpose: Rho-associated kinase 2 (ROCK2) was shown to be implicated in regulation of autoimmunity in mice and humans1. Previous findings demonstrated that oral administration of…
Abstract Number: 926 • 2016 ACR/ARHP Annual Meeting
Increased Concentration of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Predate Onset of Rheumatoid Arthritis
Linda Johansson¹, Lisbeth Ärlestig¹, Heidi Kokkonen² and Solbritt Rantapaa-Dahlqvist³, ¹Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ³Umeå University, Department of Public Health and Clinical Medicine/ Rheumatology, Umeå, Sweden
Background/Purpose: Receptor activator of nuclear factor κB ligand (RANKL) an important regulator of bone metabolism has a key role in local bone destruction and osteoporosis…
Abstract Number: 1989 • 2016 ACR/ARHP Annual Meeting
Mechanism of STAT3 Gain-of-Function in a Patient with JIA
Tiphanie P. Vogel^1,2, Nermina Saucier³, Molly P. Keppel³ and Megan A. Cooper^3,4, ¹Pediatrics/Rheumatology, Washington University in St. Louis, St. Louis, MO, ²Internal Medicine/Rheumatology, Washington University in St. Louis, Saint Louis, MO, ³Pediatrics/Rheumatology, Washington University in St. Louis, Saint Louis, MO, ⁴Pathology and Immunology, Washington University in St. Louis, Saint Louis, MO
Background/Purpose: The transcription factor signal transducer and activator of transcription 3 (STAT3) mediates cytokine-induced changes in gene expression. STAT3 is classically activated by phosphorylation followed…
Abstract Number: 1096 • 2016 ACR/ARHP Annual Meeting
Augmentation of Wnt Signaling By IL-1β in Fibroblast-like Synoviocytes
Satoshi Yamasaki¹, Yusuke Yoshida² and Eiji Sugiyama², ¹Hiroshima University Hospital, Hiroshima, Japan, ²Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Wnt family proteins canonically stabilize β-catenin to activate T-cell factor (TCF) for the transcription of several genes, including Runx2, which is important for osteoblastogenesis.…
Abstract Number: 2103 • 2016 ACR/ARHP Annual Meeting
Peripheral Blood B Cells Are Expanded and Their Cytokine Expression Is Dysregulated in Juvenile Dermatomyositis
Meredyth Wilkinson¹, Christopher Piper², Georg Otto³, Claire Deakin⁴, Stefanie Dowle³, Stefania Simou⁵, Daniel Kelberman³, Yiannis Ioannou⁶, Claudia Mauri⁷, Elizabeth Jury⁸, David Isenberg⁹, Lucy R Wedderburn¹⁰ and Kiran Nistala¹¹, ¹Division of Medicine, University College London, London, United Kingdom, ²Rheumatology, University College London, London, United Kingdom, ³National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ⁴Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁶Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁷Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom, ⁸Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ⁹University College Hospital, London, London, United Kingdom, ¹⁰Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ¹¹Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare form of childhood autoimmune myositis that presents with proximal muscle weakness and heliotrope rash. B cells are strongly…
Abstract Number: 1124 • 2016 ACR/ARHP Annual Meeting
IL37 Rescues Human OA Cartilage Explants from GAG Release
Ellen van Geffen¹, Arjan van Caam², Henk van Beuningen², Elly Vitters², Esmeralda Blaney Davidson² and Peter M. van der Kraan², ¹Experimential Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: In healthy cartilage, there is a balance between anabolic and catabolic activities of chondrocytes that maintains the functional integrity of the extracellular matrix. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.